Addex R&D Day Highlights Broadened Therapeutic Potential of Allosteric Modulation Platform to Include Cytokine Receptors as well as GPCRs

Addex Achieves Second Milestone in Parkinson’s Disease Collaboration with Merck & Co., Inc.

Addex to Host R&D Day on July 16

Addex Partner Starts First-Ever Clinical Trial of an mGluR Positive Allosteric Modulator novel approach has potential for treatment of multiple cns disorders

Glutamate Receptor “mGluR5” Implicated in GERD

Addex Presents Data on ADX10059 at the AAN

Addex Shareholders Approve All Board Proposals at 2009 AGM

Addex Pharmaceuticals 2008 Financial Results

Addex 2008 Full Year Financial Results Next Tuesday

Addex Successfully Completes ADX48621 Phase I Program